Page last updated: 2024-12-06
oxomemazine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
oxomemazine: selective for M1 muscarinic receptors [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 19396 |
| CHEMBL ID | 2104734 |
| CHEBI ID | 135408 |
| SCHEMBL ID | 423634 |
| MeSH ID | M0306120 |
Synonyms (86)
| Synonym |
|---|
| AC-15943 |
| oxomemazine |
| 10h-phenothiazine-10-propanamine, n,n,.beta.-trimethyl-, 5,5-dioxide |
| 3-(5,5-dioxido-10h-phenothiazin-10-yl)-n,n,2-trimethylpropan-1-amine |
| 3689-50-7 |
| 10-(3-(dimethylamino)-2-methylpropyl)phenothiazine 5,5-dioxide |
| oxomemazina [inn-spanish] |
| oxomemazine [inn:dcf] |
| doxergan |
| phenothiazine, 10-(3-(dimethylamino)-2-methylpropyl)-, 5,5-dioxide |
| dioxo-9,9-(dimethylamino-3-methyl-2-propyl)-10-phenothiazine [french] |
| oxymemazine |
| dysedon |
| imakol |
| alimemazine s,s-dioxide |
| 10-(3-(dimethylamino)-2-methylpropyl)phenothiazine-5,5-dioxide |
| oxomemazinum [inn-latin] |
| dosegran |
| brn 0289178 |
| rp 6847 |
| einecs 222-996-8 |
| oxomemazine (inn) |
| doxergan (tn) |
| D07401 |
| CHEBI:135408 |
| 3-(5,5-dioxophenothiazin-10-yl)-n,n,2-trimethylpropan-1-amine |
| NCGC00182075-02 |
| NCGC00182075-03 |
| CHEMBL2104734 |
| 6487-rp |
| oplex |
| rp-6847 |
| 6847-rp |
| exe-top |
| trimeprazine 5,5-dioxide |
| AKOS015962134 |
| 4-27-00-01270 (beilstein handbook reference) |
| oxomemazinum |
| oxomemazina |
| dioxo-9,9-(dimethylamino-3-methyl-2-propyl)-10-phenothiazine |
| 6847 r.p. |
| unii-305mb38v1c |
| 305mb38v1c , |
| oxomemazin |
| oxomemazine [inn] |
| oxomemazine [mart.] |
| 156576-01-1 |
| oxomemazine [mi] |
| (+/-)-oxomemazine |
| oxomemazine [who-dd] |
| SCHEMBL423634 |
| smr004701064 |
| MLS006009989 |
| 3-(5,5-dioxido-10h-phenothiazin-10-yl)-n,n,2-trimethyl-1-propanamine # |
| QTQPVLDZQVPLGV-UHFFFAOYSA-N |
| 6487 rp |
| 6847 rp |
| phenothiazine, 10-[3-(dimethylamino)-2-methylpropyl]-, 5,5-dioxide |
| 10-(3-(dimethylamino)-2-methylpropyl)-10h-phenothiazine 5,5-dioxide |
| FT-0698324 |
| DTXSID5023405 |
| unii-5gp9538p4s |
| 10h-phenothiazine-10-propanamine, n,n,beta-trimethyl-, 5,5-dioxide, (-)- |
| 10h-phenothiazine-10-propanamine, n,n,beta-trimethyl-, 5,5-dioxide, (+)- |
| unii-q824sgh3rn |
| SR-01000883964-1 |
| sr-01000883964 |
| (-)-oxomemazine |
| 10h-phenothiazine-10-propanamine, n,n,.beta.-trimethyl-, 5,5-dioxide, (-)- |
| oxomemazine, (-)- |
| 174508-13-5 |
| oxomemazine, (+)- |
| 10h-phenothiazine-10-propanamine, n,n,.beta.-trimethyl-, 5,5-dioxide, (+)- |
| 5GP9538P4S , |
| 174508-14-6 |
| Q824SGH3RN , |
| (+)-oxomemazine |
| F20164 |
| oxomemazine 1.0 mg/ml in methanol |
| trimeprazine sulphone; oxomemazine |
| Q3359071 |
| mfcd00868197 |
| DB13820 |
| HY-136587 |
| CS-0131898 |
| MS-24971 |
Research Excerpts
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " The proposed methods have been applied successfully for the analysis of the drug in pure form and in its dosage forms." | ( Extractive spectrophotometric methods for the determination of oxomemazine hydrochloride in bulk and pharmaceutical formulations using bromocresol green, bromocresol purple and bromophenol blue. El-Didamony, AM, 2005) | 0.57 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| phenothiazines | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Pathways (1)
| Pathway | Proteins | Compounds |
|---|---|---|
| Oxomemazine H1-Antihistamine Action | 8 | 7 |
Research
Studies (4)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 80.17
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (80.17) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (20.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 4 (80.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||